<PAGE> 1
=====================================================================
Filed pursuant to Rule 424(b)(3) under the Securities Act of 1933
Registration Statement on Form S-8 (No. 33-56844)
PROSPECTUS SUPPLEMENT
(to the Prospectus, dated January 7, 1993)
IMMUNOMEDICS, INC.
3,000,000 Shares
Common Stock, $.01 Par Value
This Prospectus Supplement constitutes an essential part of the
Prospectus, dated January 7, 1993, of Immunomedics, Inc. and
should be read in conjunction with such Prospectus.
The information set forth below supersedes the information
contained under "Selling Stockholders" in the Prospectus. All
capitalized terms used herein have the meanings given such terms
in the Prospectus.
SELLING STOCKHOLDERS
The shares of Common Stock to which this Prospectus relates
are being registered for reoffers and resales by Selling
Stockholders of the Company who may acquire such shares pursuant
to the exercise of options granted or to be granted under the
Plan. The Selling Stockholders named below may resell all, a
portion, or none of the shares that they acquire or may acquire
pursuant to the exercise of options under the Plan.
Participants under the Plan who are deemed to be
"affiliates" of the Company who acquire Common Stock under the
Plan may be added to the Selling Stockholders listed below from
time to time, either by means of a post-effective amendment to
the Registration Statement or by use of a prospectus supplement
filed pursuant to Rule 424(c) under the 1933 Act. An "affiliate"
is defined in Rule 405 under the 1933 Act as a "person that
directly, or indirectly, through one or more intermediaries,
controls, or is controlled by, or is under common control with",
the Company.
The following table sets forth certain information
concerning the Selling Stockholders as of the date of this
Prospectus. Except as disclosed in the table, none of the
Selling Stockholders listed below has, or within the past three
years has had, any position, office or other material
relationship with the Company or any of its predecessors or
affiliates.
<PAGE> 2
<TABLE>
<CAPTION>
Maximum Number of
Shares Subject to
Outstanding Options
Position With Which May Be
Name The Company Reoffered Hereby 1
___________________________________________________________________________
<S> <C> <C>
David M. Goldenberg Chairman of the Board, 375,000
Chief Executive Officer
and Director
W. Robert Friedman, Jr. Director 10,000
Marvin E. Jaffe Director 40,000
Richard R. Pivirotto Director 50,000
Warren W. Rosenthal Director 50,000
Richard C. Williams Director 50,000
Hans J. Hansen Vice President - 235,000
Research and Development
Robert F. Komenda Vice President - 25,000
Finance & Administration
Carl M. Pinsky Vice President - 182,500
Medical Affairs
Joseph E. Presslitz Vice President - 148,500
Regulatory Affairs
___________________________________________________________________________
</TABLE>
1. As of November 28, 1997. Does not constitute a commitment
to sell any or all of the stated number of shares of Common
Stock. The number of shares offered shall be determined from
time to time by each Selling Stockholder at his sole discretion.
The date of this Prospectus Supplement is December 1, 1997.
<PAGE> 3
